prof. dr. M.J.H. Kas
1. EU-AIMS: Translational Endpoints in Autism (Innovative Medicine Initiative (IMI) project)
Aim: Development and implementation of translational approaches to accelerate drug discovery for Autism Spectrum Disorders (ASD). As a principal investigator in the project, my contributions concern the development of behavioral and cognitive phenotyping battery for developing and adult mice. Several genetic mouse models for ASD have been tested and revealed distinct social and repetitive behavior trajectories. These behavioral phenotypes will now be used for the genetic mapping of loci underlying these sophisticated phenotypes relevant to ASD. Furthermore, we have implemented integrated EEG-behavioral analyses in ASD mouse models, critically important to simultaneously study neural circuit functioning during specific behavioral events. (https://euaims.eu/)
2. PRISM: Psychiatric Ratings using Intermediate Stratified Markers (Innovative Medicine Initiative (IMI) project)
Aim: This project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. As the project coordinator of this EU Innovative Medicine Initiative (IMI) project, we aim to unpick the biological reasons underlying social withdrawal, which is a common early symptom of, Schizophrenia, Alzheimer’s disease and Major Depressive Disorder. The PRISM project started on April 1 2016, and is a EUR €16.5 million public-private cooperation, uniting researchers from European academic centres, and major pharmaceutical companies. (www.prism-project.eu)
3. BeHapp: Longitudinal monitoring of adolescent social behavior in real life and to predict onset of behavioral disorders.
Aim: Providing novel insights into normal social behaviors of young individuals, and identify longitudinal deviations of social profiles that may predict risk for developing behavioral disorders. For these studies, newly developed smartphone app technology will be used to study human social exploration behavior. (www.behapp.org)
4. SMARD: Monitoring and cognition modification against recurrence of depression (Dutch Brain Foundation).
We aim to improve our understanding of the neurobiological background of resilience and who is most at risk for the recurrence of depression. For these studies, newly developed smartphone app technology will be used.
5. ROADMAP: Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform (Innovative Medicine Initiative (IMI) project).
The aim of ROADMAP is to provide the foundation for a Europe-wide RWE (real world evidence) platform on Alzheimer's Disease (AD). The basis for this platform will be a series of scalable, transferable data integration methods and tools for patient outcomes, developed and tested through pilot projects (such as implementation and validation of smartphone technology for behavioural assessments). In parallel, ROADMAP will develop tools for stakeholder engagement and understanding of health economics impact of a RWE approach in AD. (www.roadmap-alzheimer.org)
6. EQIPD: The European Quality In Preclinical Data project (Innovative Medicine Initiative (IMI) project)
EQIPD aims to inform the design of future preclinical studies to minimise variance and enhance reproducibility by compiling preclinical research data across industry and academia to determine the primary variables in study design and data analysis that affect data quality and levels of robustness. (www.eqipd.org)
7. Social factors in cognitive decline and dementia: towards an early intervention approach (ZonMW Memorable project).
Environment plays an important role in the development of dementia. Environmental factors that indicate poor social health such as lack of social support and loneliness are presumed to increase the risk of dementia. In this project, we put forward the hypothesis that factors improving social health will slow down the development of cognitive decline and dementia by influencing brain health. We use an integrated analysis of data on social health, cognitive functioning, brain morphology and neuro-inflammation in humans and mice, both with high or low risk for dementia development.
8. Early developmental processes underlying sensory deficits in neurodevelopmental disorders (ZonMW TOP project)
Autism spectrum disorder (ASD) represents a group of complex neurodevelopmental disorders of strikingly high incidence. The traditional clinical features of ASD are weaknesses in social communicative abilities and restricted interests and repetitive behaviors. As now formally recognized in the DSM-5, children with ASD frequently suffer from disturbances in sensory reactivity. In fact, sensory abnormalities are one of the most prevalent symptoms of ASD, reported in up to 87% of individuals. In this project, We aim to unravel the causal relationship between aberrations in early activity patterns, miss-wiring of brain circuits, and sensory malfunction in later life.
|Last modified:||20 March 2018 11.51 a.m.|